EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.
Malapelle U, et al.
Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18.
Cancer Cytopathol. 2013.
PMID: 23780873
Free article.